Author

O. Terrier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Approach:experimental assay· 8 Research Focus:drug response / drug discovery· 6 Assay:bulk RNA-seq· 4 Research Focus:host-pathogen & immune response· 4 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. Rosa-Calatrava· 9 shared A. Pizzorno· 8 shared B. Lina· 7 shared B. Padey· 7 shared T. Julien· 7 shared A. Traversier· 6 shared J. Dubois· 5 shared C. Nicolas de Lamballerie· 4 shared

Activity by Year

2018-2022 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

M. Rosa-Calatrava

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro

H. R. Jonsdottir, D. Siegrist, T. Julien, B. Padey, M. Bouveret, O. Terrier, A. Pizzorno, S. Huang, K. Samby, T. Wells, B. Boda, M. Rosa-Calatrava, O. Engler, S. Constant

The paper evaluates antiviral effects of 95 single compounds and 30 combinations, showing that molnupiravir with other drugs inhibits SARS-CoV-2 replication in human nasal epithelium in vitro.

bioRxiv · Jan 10, 2022Microbiology

A novel effective live-attenuated human metapneumovirus vaccine candidate produced in the serum-free suspension DuckCelt-T17 cell platform

C. Chupin, A. Pizzorno, A. Traversier, P. Brun, D. Ogonczyk-makowska, B. Padey, C. Milesi, V. Duliere, E. Laurent, T. Julien, M. Galloux, B. Lina, J.-F. Eleouet, K. Moreau, M.-E. Hamelin, , M. Rosa-Calatrava

This study evaluates the use of DuckCelt-T17 avian cells for producing a live-attenuated HMPV vaccine candidate, showing its efficiency and scalability.

bioRxiv · Aug 30, 2021 · PreprintImmunology

Flagellin from Pseudomonas aeruginosa modulates SARS-CoV-2 infectivity in CF airway epithelial cells by increasing TMPRSS2 expression

M. Ruffin, J. Bigot, C. Calmel, J. Mercier, A. Pizzorno, M. Rosa-Calatrava, H. Corvol, V. Balloy, O. Terrier, L. Guillot

This study shows that flagellin from Pseudomonas aeruginosa increases TMPRSS2 expression in airway epithelial cells, enhancing SARS-CoV-2 infectivity, particularly in CFTR-deficient cells.

bioRxiv · Aug 24, 2020 · PreprintPathology

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization

B. Wang, D. Asarnow, W.-H. Lee, C.-W. Huang, B. Faust, P. M. L. Ng, E. Z. X. Ngoh, M. Bohn, D. Bulkley, A. Pizzorno, H. C. Tan, C. Y. Lee, R. A. Minhat, O. Terrier, M. K. Soh, , C.-I. Wang

This study identifies a potent SARS-CoV-2 neutralizing antibody, 5A6, that binds bivalently to two RBDs on the spike protein, showing resistance to key mutations.

bioRxiv · Jul 14, 2020 · PreprintMicrobiology

Human Respiratory Syncytial Virus-induced immune signature of infection revealed by transcriptome analysis of clinical pediatric nasopharyngeal swab samples

C. Nicolas de Lamballerie, A. Pizzorno, J. Dubois, B. Padey, T. Julien, A. Traversier, J. Carbonneau, E. Orcel, B. Lina, M.-E. Hamelin, M. Roche, J. Textoris, G. Boivin, C. Legras-Lachuer, O. Terrier, M. Rosa-Calatrava

This study identifies an HRSV-induced immune signature in pediatric nasal wash samples using transcriptome analysis.

bioRxiv · May 20, 2020Microbiology

Transcriptional profiling of immune and inflammatory responses in the context of SARS-CoV-2 fungal superinfection in a human airway epithelial model

C. Nicolas de Lamballerie, A. Pizzorno, J. Fouret, L. szpiro, B. Padey, J. Dubois, T. Julien, A. Traversier, V. Duliere, P. Brun, B. Lina, M. Rosa-Calatrava, O. Terrier

The paper compares the transcriptional responses of SARS-CoV-2 and Aspergillus superinfection in human airway epithelial models, identifying unique immune and inflammatory signatures.

bioRxiv · May 19, 2020Microbiology

Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus

O. Terrier, S. Dilly, M.-A. Pizzorno, J. Henri, F. Berenbaum, B. Lina, B. Feve, F. Adnet, M. Sabbah, M. Rosa-Calavatra, V. Marechal, A. Slama-Schwok

This study evaluates naproxen's antiviral activity against SARS-CoV-2 and Influenza A virus, showing it inhibits viral replication and protects respiratory epithelia.

bioRxiv · Apr 30, 2020 · PreprintMicrobiology

Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia

A. Pizzorno, B. Padey, T. Julien, S. Trouillet-Assant, A. Traversier, E. Errazuriz-Cerda, J. Fouret, J. Dubois, A. Gaymard, X. Lescure, V. Duliere, P. Brun, S. Constant, J. Poissy, B. Lina, , M. Rosa-Calatrava

The paper characterizes SARS-CoV-2 infection in nasal and bronchial airway epithelial models and evaluates the antiviral efficacy of remdesivir and its combination with diltiazem.

bioRxiv · Mar 31, 2020Microbiology

Strain-dependent impact of G and SH deletions provide new insights for live-attenuated HMPV vaccine development

J. Dubois, A. Pizzorno, M.-H. Cavanagh, B. Padey, C. Nicolas de Lamballerie, O. Uyar, M.-C. Venable, J. Carbonneau, A. Traversier, T. Julien, C. Couture, B. Lina, M.-E. Hamelin, O. Terrier, M. Rosa-Calatrava, G. Boivin

This study evaluates strain-dependent effects of G and SH deletions in HMPV to inform live-attenuated vaccine development, finding that SH-deleted A1/C-85473 virus is attenuated and protective in mice.

bioRxiv · Sep 25, 2019Microbiology

Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

M. A. Pizzorno, O. Terrier, C. Nicolas de Lamballerie, T. Julien, B. Padey, A. Traversier, M. Roche, M.-E. Hamelin, C. Rheaume, S. Croze, V. Escuret, J. Poissy, B. Lina, C. Legras-Lachuer, J. Textoris, , M. Rosa-Calatrava

This paper identifies 35 FDA-approved drugs with antiviral potential against influenza using transcriptomic signatures, validates 31 in vitro, and highlights diltiazem as a promising candidate for Phase II clinical trials.

bioRxiv · Aug 27, 2018Microbiology